Reply to Stowasser et al.: Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good

Ganesh Raghu^{1

2

3}, Thomas R Fleming⁴, Fernando J Martinez⁵

Affiliations

¹ Center for Interstitial Lung Diseases.
² Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine.
³ Department of Laboratory Medicine and Pathology, and.
⁴ Department of Biostatistics, University of Washington, Seattle, Washington; and.
⁵ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.

Comment

Ganesh Raghu et al. Am J Respir Crit Care Med. 2024.

. 2024 Aug 1;210(3):368-369.

doi: 10.1164/rccm.202404-0789LE.

Ganesh Raghu^{1

2

3}, Thomas R Fleming⁴, Fernando J Martinez⁵

¹ Center for Interstitial Lung Diseases.
² Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine.
³ Department of Laboratory Medicine and Pathology, and.
⁴ Department of Biostatistics, University of Washington, Seattle, Washington; and.
⁵ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York.

No abstract available

Comment on

Assessing How Patients Feel, Function, and Survive in Idiopathic Pulmonary Fibrosis: The Best Is the Enemy of the Good.
Stowasser S, Cosgrove GP, White ES. Stowasser S, et al. Am J Respir Crit Care Med. 2024 Aug 1;210(3):367-368. doi: 10.1164/rccm.202402-0337LE. Am J Respir Crit Care Med. 2024. PMID: 38820300 Free PMC article. No abstract available.

1. Raghu G, Ghazipura M, Fleming TR, Aronson KI, Behr J, Brown KK, et al. Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on ‘feels, functions, survives’. Report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency. Am J Respir Crit Care Med . 2024;209:647–669. - PubMed